KIDS vs. NVCR, LMAT, CNMD, ENOV, EYE, TNDM, CDRE, LQDA, AORT, and SSII
Should you be buying OrthoPediatrics stock or one of its competitors? The main competitors of OrthoPediatrics include NovoCure (NVCR), LeMaitre Vascular (LMAT), CONMED (CNMD), Enovis (ENOV), National Vision (EYE), Tandem Diabetes Care (TNDM), Cadre (CDRE), Liquidia (LQDA), Artivion (AORT), and SS Innovations International (SSII). These companies are all part of the "medical equipment" industry.
OrthoPediatrics vs. Its Competitors
OrthoPediatrics (NASDAQ:KIDS) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
OrthoPediatrics has a net margin of -15.00% compared to NovoCure's net margin of -25.93%. OrthoPediatrics' return on equity of -5.78% beat NovoCure's return on equity.
NovoCure received 161 more outperform votes than OrthoPediatrics when rated by MarketBeat users. However, 64.43% of users gave OrthoPediatrics an outperform vote while only 62.98% of users gave NovoCure an outperform vote.
OrthoPediatrics has higher earnings, but lower revenue than NovoCure. OrthoPediatrics is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.
In the previous week, NovoCure had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.78 beat NovoCure's score of 0.48 indicating that OrthoPediatrics is being referred to more favorably in the media.
OrthoPediatrics presently has a consensus price target of $35.83, suggesting a potential upside of 64.98%. NovoCure has a consensus price target of $32.83, suggesting a potential upside of 80.40%. Given NovoCure's higher probable upside, analysts clearly believe NovoCure is more favorable than OrthoPediatrics.
69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 32.7% of OrthoPediatrics shares are held by insiders. Comparatively, 6.3% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
OrthoPediatrics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.
Summary
OrthoPediatrics beats NovoCure on 10 of the 18 factors compared between the two stocks.
Get OrthoPediatrics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OrthoPediatrics Competitors List
Related Companies and Tools
This page (NASDAQ:KIDS) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy KIDS Stock Free KIDS Stock Alerts